Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect
出版年份 2014 全文链接
标题
Pharmacologic Blockade of JAK1/JAK2 Reduces GvHD and Preserves the Graft-Versus-Leukemia Effect
作者
关键词
-
出版物
PLoS One
Volume 9, Issue 10, Pages e109799
出版商
Public Library of Science (PLoS)
发表日期
2014-10-08
DOI
10.1371/journal.pone.0109799
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Activity of therapeutic JAK 1/2 blockade in graft-versus-host disease
- (2014) S. Spoerl et al. BLOOD
- Selective JAK2 Inhibition Specifically Decreases Hodgkin Lymphoma and Mediastinal Large B-cell Lymphoma Growth In Vitro and In Vivo
- (2014) Y. Hao et al. CLINICAL CANCER RESEARCH
- Myeloid-derived suppressor cells in breast cancer
- (2013) Joseph Markowitz et al. BREAST CANCER RESEARCH AND TREATMENT
- AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors
- (2013) E. R. Plimack et al. ONCOLOGIST
- IFN R signaling mediates alloreactive T-cell trafficking and GVHD
- (2012) J. Choi et al. BLOOD
- The Role of JAK Pathway Dysregulation in the Pathogenesis and Treatment of Acute Myeloid Leukemia
- (2012) H. J. Lee et al. CLINICAL CANCER RESEARCH
- Sequencing a mouse acute promyelocytic leukemia genome reveals genetic events relevant for disease progression
- (2011) Lukas D. Wartman et al. JOURNAL OF CLINICAL INVESTIGATION
- The JAK inhibitor AZD1480 regulates proliferation and immunity in Hodgkin lymphoma
- (2011) E Derenzini et al. Blood Cancer Journal
- NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic HSCT: Graft-versus-Tumor/Leukemia Reaction
- (2010) Jeffrey S. Miller et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Constitutively active Stat5b in CD4+ T cells inhibits graft-versus-host disease lethality associated with increased regulatory T-cell potency and decreased T effector cell responses
- (2010) C. Vogtenhuber et al. BLOOD
- In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia
- (2010) J. Choi et al. BLOOD
- CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms
- (2010) J. W. Tyner et al. BLOOD
- Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms
- (2010) A. Quintas-Cardama et al. BLOOD
- Bone marrow myeloid-derived suppressor cells (MDSCs) inhibit graft-versus-host disease (GVHD) via an arginase-1-dependent mechanism that is up-regulated by interleukin-13
- (2010) S. L. Highfill et al. BLOOD
- Recent patents in the discovery of small molecule inhibitors of JAK3
- (2010) Lawrence J Wilson EXPERT OPINION ON THERAPEUTIC PATENTS
- Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease
- (2009) T. Yi et al. BLOOD
- New perspectives on the biology of acute GVHD
- (2009) S Paczesny et al. BONE MARROW TRANSPLANTATION
- The JAK2 Inhibitor AZD1480 Potently Blocks Stat3 Signaling and Oncogenesis in Solid Tumors
- (2009) Michael Hedvat et al. CANCER CELL
- Efficacy of TG101348, a Selective JAK2 Inhibitor, in Treatment of a Murine Model of JAK2V617F-Induced Polycythemia Vera
- (2008) Gerlinde Wernig et al. CANCER CELL
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreFind the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
Search